This co-expression has been implicated in tumour progression, as FasL can act in an autocrine or juxtacrine Fas-dependent manner to promote tumour growth (Lambert et al, 2003; Houston and O'Connell, 2004). The gene discussed is FASLG; the disease is neoplasm.